2018
Comparison of Residual Risk–Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies
Wei W, Kurita T, Hess KR, Sanft T, Szekely B, Hatzis C, Pusztai L. Comparison of Residual Risk–Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. JAMA Oncology 2018, 4: e175092-e175092. PMID: 29372234, PMCID: PMC5885272, DOI: 10.1001/jamaoncol.2017.5092.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantEligibility DeterminationFemaleHumansLymph NodesLymphatic MetastasisMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualPatient SelectionPrognosisRandomized Controlled Trials as TopicReproducibility of ResultsResearch DesignRetrospective StudiesRisk FactorsSurvival AnalysisTrastuzumabTumor BurdenWatchful WaitingYoung AdultConceptsTumor sizeAdjuvant trialsEligibility criteriaNodal statusClinical trialsResidual riskEarly-stage breast cancerAdjuvant clinical trialsBaseline prognostic riskFuture adjuvant trialsResidual risk estimatesRisk of recurrenceBreast cancer therapyRisk thresholdTrial powerClinical trial powerTrial eligibilityAdjuvant therapyCare therapyConsecutive patientsPrognostic riskPatient eligibilityTrial populationPatient cohortControl arm
2017
Discussion of: “Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?”
Chagpar AB, Horowitz N, Sanft T, Wilson LD, Silber A, Killelea B, Moran MS, DiGiovanna MP, Hofstatter E, Chung G, Pusztai L, Lannin DR. Discussion of: “Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?”. The American Journal Of Surgery 2017, 214: 1089-1090. PMID: 28987415, DOI: 10.1016/j.amjsurg.2017.09.025.Commentaries, Editorials and LettersAssociation of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer
Chagpar AB, Hatzis C, Pusztai L, DiGiovanna MP, Moran M, Mougalian S, Sanft T, Evans S, Hofstatter E, Wilson LD, Lannin DR. Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer. Annals Of Surgical Oncology 2017, 24: 3073-3081. PMID: 28766195, DOI: 10.1245/s10434-017-5936-x.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalLN evaluationPositive breast cancerOverall survivalBreast cancerHormone receptor-positive breast cancerWomen Aged 70 YearsReceptor-positive breast cancerLymph node evaluationCancer-specific survivalLower hazard rateLN surgeryBetter OSPatient ageSEER databasePatient selectionTumor characteristicsSEER dataPatientsNode evaluationHormone receptorsCancerSurvivalTreatment variablesNCDB
2013
Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA
Rae JM, Regan MM, Thibert JN, Gersch C, Thomas D, Leyland-Jones B, Viale G, Pusztai L, Hayes DF, Skaar T, Van Poznak C. Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA. Journal Of The National Cancer Institute 2013, 105: 1332-1334. PMID: 23958736, PMCID: PMC3888280, DOI: 10.1093/jnci/djt204.Peer-Reviewed Original ResearchConceptsCYP2D6 genotypeCYP2D6 metabolic phenotypeBreast cancer patientsMetabolic phenotypeAnti-estrogen tamoxifenCancer clinical trialsCancer patientsClinical trialsTumor alterationsGermline DNAConflicting resultsPatientsTumorsTissue sourcesGenotype association studiesConcordanceGenotypesPhenotypeAssociation studiesFFPETTamoxifenEndoxifenWBCCYP2D6Trials
2007
Standardizing Slide-Based Assays in Breast Cancer: Hormone Receptors, HER2, and Sentinel Lymph Nodes
Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Standardizing Slide-Based Assays in Breast Cancer: Hormone Receptors, HER2, and Sentinel Lymph Nodes. Clinical Cancer Research 2007, 13: 2831-2835. PMID: 17504980, DOI: 10.1158/1078-0432.ccr-06-2522.Peer-Reviewed Original ResearchConceptsReceptor statusClinical practiceHormone receptor statusProgesterone receptor statusBreast cancer careBreast cancer patientsSentinel lymph nodesDaily clinical practiceCurrent clinical practiceSignificant unmet needFalse-positive result ratesLymph nodesCancer careCancer patientsHER2 statusBreast cancerEstrogen receptorImmunohistochemistry techniquesUnmet needResult rateHormone receptorsPreanalytic conditionsNovel diagnosticsCareReceptors
2004
Prognostic significance of phosphorylated P38 mitogen‐activated protein kinase and HER‐2 expression in lymph node‐positive breast carcinoma
Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS. Prognostic significance of phosphorylated P38 mitogen‐activated protein kinase and HER‐2 expression in lymph node‐positive breast carcinoma. Cancer 2004, 100: 499-506. PMID: 14745865, DOI: 10.1002/cncr.11940.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBiopsy, NeedleBreast NeoplasmsCombined Modality TherapyFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryLymph NodesMastectomyMiddle AgedMitogen-Activated Protein KinasesNeoplasm StagingP38 Mitogen-Activated Protein KinasesProbabilityPrognosisProportional Hazards ModelsReceptor, ErbB-2Risk AssessmentSensitivity and SpecificitySurvival AnalysisTreatment OutcomeConceptsLymph node positive breast carcinomaNode-positive breast carcinomaProgression-free survivalP-p38 MAPKShorter progression-free survivalHER-2 expressionP-p38 MAPK expressionBreast carcinomaAdjuvant chemotherapyMAPK expressionKi-67Phosphorylated p38 MAPK expressionInitial cancer surgeryPrimary breast carcinomaInvasive breast carcinomaP38 MAPK expressionP38 mitogen-activated protein kinase phosphorylationPhosphorylated p38 mitogen-activated protein kinaseMitogen-activated protein kinase phosphorylationBreast carcinoma cellsAdjuvant fluorouracilMedian followCyclophosphamide chemotherapyCancer surgeryPoor outcome